Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, P.R. China.
J Transl Med. 2011 May 7;9:53. doi: 10.1186/1479-5876-9-53.
Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has been considered as a promising treatment modality for gastric cancer with peritoneal carcinomatosis (PC). However, there have also been many debates regarding the efficacy and safety of this new approach. Results from experimental animal model study could help provide reliable information. This study was to investigate the safety and efficacy of CRS + HIPEC to treat gastric cancer with PC in a rabbit model.
VX2 tumor cells were injected into the gastric submucosa of 42 male New Zealand rabbits using a laparotomic implantation technique, to construct rabbit model of gastric cancer with PC. The rabbits were randomized into control group (n = 14), CRS alone group (n = 14) and CRS + HIPEC group (n = 14). The control group was observed for natural course of disease progression. Treatments were started on day 9 after tumor cells inoculation, including maximal removal of tumor nodules in CRS alone group, and maximal CRS plus heperthermic intraperitoneal chemoperfusion with docetaxel (10 mg/rabbit) and carboplatin (40 mg/rabbit) at 42.0 ± 0.5°C for 30 min in CRS + HIPEC group. The primary endpoint was overall survival (OS). The secondary endpoints were body weight, biochemistry, major organ functions and serious adverse events (SAE).
Rabbit model of gastric cancer with PC was successfully established in all animals. The clinicopathological features of the model were similar to human gastric PC. The median OS was 24.0 d (95% confidence interval 21.8 - 26.2 d ) in the control group, 25.0 d (95% CI 21.3 - 28.7 d ) in CRS group, and 40.0 d (95% CI 34.6 - 45.4 d ) in CRS + HIPEC group (P = 0.00, log rank test). Compared with CRS only or control group, CRS + HIPEC could extend the OS by at least 15 d (60%). At the baseline, on the day of surgery and on day 8 after surgery, the peripheral blood cells counts, liver and kidney functions, and biochemistry parameters were all comparable. SAE occurred in 0 animal in control group, 2 animals in CRS alone group including 1 animal death due to anesthesia overdose and another death due to postoperative hemorrhage, and 3 animals in CRS + HIPEC group including 1 animal death due to anesthesia overdose, and 2 animal deaths due to diarrhea 23 and 27 d after operation.
In this rabbit model of gastric cancer with PC, CRS alone could not bring benefit while CRS + HIPEC with docetaxel and carboplatin could significantly prolong the survival with acceptable safety.
细胞减灭术(CRS)加腹腔热灌注化疗(HIPEC)已被认为是一种有前途的治疗胃癌伴腹膜转移(PC)的方法。然而,对于这种新方法的疗效和安全性也存在许多争议。来自实验动物模型研究的结果可以提供可靠的信息。本研究旨在探讨 CRS+HIPEC 治疗兔胃癌伴 PC 的安全性和疗效。
采用剖腹植入技术将 VX2 肿瘤细胞注入 42 只雄性新西兰兔的胃黏膜下层,构建兔胃癌伴 PC 模型。将兔子随机分为对照组(n=14)、CRS 组(n=14)和 CRS+HIPEC 组(n=14)。对照组观察疾病自然病程。治疗于肿瘤细胞接种后第 9 天开始,包括 CRS 组最大限度地切除肿瘤结节,CRS+HIPEC 组在 42.0±0.5°C 下进行最大的腹腔热灌注化疗,用多西紫杉醇(10mg/兔)和卡铂(40mg/兔)30min。主要终点是总生存期(OS)。次要终点是体重、生化、主要器官功能和严重不良事件(SAE)。
所有动物均成功建立了胃癌伴 PC 的兔模型。该模型的临床病理特征与人胃癌 PC 相似。对照组中位 OS 为 24.0d(95%置信区间 21.8-26.2d),CRS 组为 25.0d(95%CI 21.3-28.7d),CRS+HIPEC 组为 40.0d(95%CI 34.6-45.4d)(P=0.00,对数秩检验)。与 CRS 组或对照组相比,CRS+HIPEC 至少可将 OS 延长 15d(60%)。在基线、手术当天和手术后第 8 天,外周血白细胞计数、肝肾功能和生化参数均无差异。对照组 0 只动物发生 SAE,CRS 组 2 只动物发生 SAE,包括 1 只动物因麻醉过量死亡,另 1 只动物因术后出血死亡,CRS+HIPEC 组 3 只动物发生 SAE,包括 1 只动物因麻醉过量死亡,2 只动物因腹泻于术后第 23 和 27 天死亡。
在本兔胃癌伴 PC 模型中,CRS 单独治疗不能带来益处,而 CRS+HIPEC 联合多西紫杉醇和卡铂可显著延长生存期,安全性可接受。